first_imgThursday 21 October 2010 7:38 pm by Taboolaby TaboolaSponsored LinksSponsored LinksPromoted LinksPromoted LinksYou May LikeMisterStoryWoman Files For Divorce After Seeing This Photo – Can You See Why?MisterStoryTotal PastThe Ingenious Reason There Are No Mosquitoes At Disney WorldTotal PastNoteabley25 Funny Notes Written By StrangersNoteableyMoneyPailShe Was A Star, Now She Works In ScottsdaleMoneyPailSerendipity TimesInside Coco Chanel’s Eerily Abandoned Mansion Frozen In TimeSerendipity TimesBrake For ItThe Most Worthless Cars Ever MadeBrake For ItBetterBe20 Stunning Female AthletesBetterBemoneycougar.comThis Proves The Osmonds Weren’t So Innocentmoneycougar.comMagellan TimesThis Is Why The Roy Rogers Museum Has Been Closed For GoodMagellan Times More From Our Partners Native American Tribe Gets Back Sacred Island Taken 160 Years Agogoodnewsnetwork.orgA ProPublica investigation has caused outrage in the U.S. this weekvaluewalk.comBrave 7-Year-old Boy Swims an Hour to Rescue His Dad and Little Sistergoodnewsnetwork.orgI blew off Adam Sandler 22 years ago — and it’s my biggest regretnypost.comRussell Wilson, AOC among many voicing support for Naomi Osakacbsnews.comKiller drone ‘hunted down a human target’ without being told tonypost.comAstounding Fossil Discovery in California After Man Looks Closelygoodnewsnetwork.orgFlorida woman allegedly crashes children’s birthday party, rapes teennypost.comPolice Capture Elusive Tiger Poacher After 20 Years of Pursuing the Show Comments ▼ WILLIAM HILLExecution Noble has reiterated its “buy” recommendation for the bookmaker saying business continues to hold up and management now expects to come out at the top end of current analyst forecasts for the current year. The broker says William Hill is managing its market position and looks better than its peers and is developing its online business well.NOVARTISEvo Securities has kept its “buy” recommendation on Novartis after it reported third quarter results ahead of expectations, with sales of $12.6bn and core earnings per share of $1.36. The broker said positives include its Diovan drug sales holding up in the light of the possible risk of substitution by generics and strong $292m sales from its generic drug Lovenox.PERNOD RICARDS&P Equity Research has kept its recommendation to “buy” Pernod at its 12-month target price of €72 following the firm’s first quarter sales update revealing 9.4 per cent organic sales growth year on year. This was ahead of expectations as emerging markets led the group’s sales increase with 20 per cent growth in the period, raising their share of sales to 37 per cent. Tags: NULL Sharecenter_img whatsapp whatsapp BEST OF THE BROKERS KCS-content last_img